{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-053527","form_type":"8-K","ticker":"BIO","cik":"0000012208","company_name":"BIO-RAD LABORATORIES, INC.","filed_at":"2022-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.628092+00:00","generated_at":"2026-06-27T04:03:43.874141+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bio-Rad targets ~9% core revenue CAGR, 28% adj. EBITDA margin by 2025 at Investor Day","bullets":["Core revenue CAGR target of ~9% from 2021 to 2025, excluding COVID-related sales and currency effects.","Adjusted EBITDA margin target of 28% in 2025, up from 20%+ target set in 2017.","Previously set 2017 targets of 3-5% revenue growth and 20%+ EBITDA margin were exceeded.","Growth drivers include ddPCR, single cell analysis, biopharma expansion, and molecular diagnostics.","Capital allocation strategy includes generating cash flow and pursuing strategic acquisitions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-053527","json":"https://secwatch.observer/filing/0001193125-22-053527.json","markdown":"https://secwatch.observer/filing/0001193125-22-053527.md","text":"https://secwatch.observer/filing/0001193125-22-053527.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/12208/000119312522053527/0001193125-22-053527-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/12208/000119312522053527/d901425d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T04:03:43.874141+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}